

OVERSUBSCRIBED SHARE PURCHASE PLAN TO CLOSE EARLY

PERTH, Australia, 25 September 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, advises that the Share Purchase Plan (**SPP**) which opened on 15 September 2025 has received applications exceeding \$5 million following strong early demand from eligible shareholders. As a result, the Directors have decided to close the SPP early to lessen the scale back of applications.

The revised closing date for the SPP is 5:00pm (Sydney time) on Friday, 26 September 2025. Applications received after that date will not be accepted under the SPP and the application monies received will be returned to the applicant in full in accordance with the terms of the SPP.

To ensure timely refunds and avoid delays, shareholders are encouraged to update their bank details with Automic Share Registry via the Investor Portal at <https://portal.automic.com.au/investor/home>. For assistance, please contact Automic at 1300 288 664 (within Australia), +61 2 9698 5414 (international) between 6:30am to 5:00pm (AWST) on business days, or email corporate.actions@automicgroup.com.au.

The Company will undertake a scale back of applications received prior to the revised closing date and may also accept applications that result in the SPP raising more than \$5 million in accordance with the terms of the SPP.

Timetable

The following timetable is indicative only and may be subject to change at the sole discretion of the Company, in compliance with the ASX Listing Rules and the Corporations Act.

Revised SPP Closing Date	26 September 2025
SPP Results announced	On or before noon (Sydney time) 3 October 2025
Shares issued and lodgement of Appendix 2A	On or before noon (Sydney time) 3 October 2025
Despatch of holding statements	On or before 6 October 2025

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com